This article was written for Silversurfers, which is now part of Rest Less.
Sponsored content
Dementia is now the leading cause of death in the UK, surpassing heart disease and cancer. Nearly 1 million people are currently living with the condition, and that number is expected to rise to 1.4 million by 2040.
With over 200 new diagnoses every day, the need for early detection and preventative care has never been more urgent. Yet, amid growing concern, there is hope.
Early diagnosis empowers individuals and families to plan, access support services, and potentially slow the disease’s progression. Unfortunately, more than a third of people with dementia do not receive a formal diagnosis, delaying care and leaving many unprepared.
Encouragingly, government-backed innovation is helping to shift the focus from reactive to preventative care. A recent £6.7 million investment is funding four dementia research projects at top UK institutions:
- University of Sheffield is developing communication tools for people with advanced dementia.
- Heriot-Watt University is working on methods to predict and slow progression.
- Northumbria University is creating rural tech hubs to improve care access.
- Imperial College London is building home-based technologies for independent living.
These projects mark a crucial turning point, prioritising independence, early intervention, and quality of life over late-stage symptom management.
Preventative dementia assessments are a key part of this new approach. These assessments help identify risk early through cognitive testing, lifestyle analysis, and brain imaging. With dementia risk now included in NHS Health Checks for adults over 40, more people can take proactive steps to protect their cognitive health.
Echelon Health are the world leading provider of preventative health assessments and have recently introduced the gold standard Dementia assessment. This private assessment integrates cutting-edge diagnostics, expert clinical evaluation, and personalised care to provide early and accurate detection, enabling timely intervention.
Recognising that no single test can definitively diagnose dementia, Echelon Health employs a multifaceted strategy combining:
- In-Depth Blood Tests: These tests assess various health markers, including haematology, renal and liver function, diabetes indicators, cholesterol profiles, thyroid function, and levels of essential vitamins such as D, B12, and folic acid. They also measure markers of inflammation, offering insights into potential contributors to cognitive decline.
- 3T MRI Brain Scan: Utilising high-resolution imaging, this scan detects structural brain changes, such as hippocampal atrophy, associated with Alzheimer’s disease. The scans are interpreted by leading neuro-specialist radiologists, ensuring precise analysis.
- Neurocognitive Assessment: Conducted by a specialist neurologist, this evaluation uses the Addenbrooke’s Cognitive Examination III (ACE-III), a tool with a 97% sensitivity rate for detecting cognitive impairments. It assesses various cognitive domains, including attention, memory, language, visuospatial skills, and executive functions.
Early diagnosis of dementia is crucial, as it allows individuals to access treatments and support systems sooner, potentially slowing disease progression and improving quality of life. Echelon Health’s comprehensive assessment empowers clients with the knowledge and resources to take proactive steps in managing their cognitive health.
For a confidential conversation with the Head of Private Clients, call 020 7580 7688, email [email protected] or visit echelon.health
